CoChat

Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study

Reilmann, Ralf, McGarry, Andrew, Grachev, Igor D, Savola, Juha-Matti, Borowsky, Beth, Eyal, Eli, Gross, Nicholas, Langbehn, Douglas, Schubert, Robin, Wickenberg, Anna Teige, Papapetropoulos, Spyros, Hayden, Michael, Squitieri, Ferdinando, Kieburtz, Karl, Landwehrmeyer, G Bernhard, Agarwal, Pinky, Anderson, Karen E, Aziz, Nasir A, Azulay, Jean-Phillippe, Bachoud-Levi, Anne C, Barker, Roger, Bebak, Agnieszka, Beuth, Markus, Biglan, Kevin, Blin, Stephanie, Bohlen, Stefan, Bonelli, Raphael, Caldwell, Sue, Calvas, Fabienne, Carlos, Jonielyn, Castagliuolo, Simona, Chong, Terrence, Chua, Phyllis, Coleman, Allison, Corey-Bloom, Jody, Cousins, Rebecca, Craufurd, David, Davison, Jill, Decorte, Eric, De Michele, Giuseppe, Dornhege, Laura, Feigin, Andrew, Gallehawk, Stephanie, Gauteul, Pascale, Gonzales, Carey, Griffith, Jane, Gustov, Alexander, Guttman, Mark, Heim, Beatrix, Heller, Hope, Hjermind, Lena, Illarioshkin, Sergey, Ivanko, Larry, Jaynes, Jessica, Jenckes, Mollie, Kaminski, Barbara, Kampstra, Anne, Konkel, Agnieszka, Kopishinskaya, Svetlana, Krystkowiak, Pierre, Komati, Suresh K, Kwako, Alexander, Lakoning, Stefan, Latipova, Guzal, Leavitt, Blair, Loy, Clement, MacFarlane, Cheryl, Madsen, Louise, Marder, Karen, Mason, Sarah, Mendis, Neila, Mendis, Tilak, Nemeth, Andrea, Nevitt, Louise, Norris, Virginia, O'Neill, Christine, Olivier, Audrey, Orth, Michael, Owens, Ashley, Panegyres, Peter, Perlman, Susan, Preston, Joy, Priller, Josef, Puch, Alicja, Quarrell, Oliver, Ragosta, Domenica, Rialland, Amandine, Rickards, Hugh, Romoli, Anna M, Ross, Christopher, Rosser, Anne, Rudzinska, Monika, Russo, Cinzina V, Saft, Carsten, Segro, Victoria, Seppi, Klaus, Shannon, Barbara, Shprecher, David, Simonin, Clemence, Skitt, Zara, Slawek, Jaroslaw, Soliveri, Paola, Sorbi, Sandro, Squitieri, Ferdinando, Suski, Valarie, Stepniak, Iwona, Sungmee, Park, Temirbaeva, Sofia, Testa, Claudia, Torvin-Moller, Anette, Uhl, Stefanie, Vangsted-Hansen, Christina, Verny, Christophe, Wall, Paola, Walker, Francis, Wasserman, Paula, Witkowski, Grzegorz, Wright, Jan, Zalyalova, Zuleykha, Zielonka, Daniel · 2019 · The Lancet Neurology
Cited by 111

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

BACKGROUND Previous trials have shown that pridopidine might reduce motor impairment in patients with Huntington's disease. The aim of this study was to ascertain whether higher doses of pridopidine than previously tested reduce motor symptoms in a dose-dependent manner while maintaining acceptable safety and tolerability. METHODS PRIDE-HD was a randomised, placebo-controlled, phase 2, dose-ranging study in adults (aged ≥21 years) with Huntington's disease at outpatient clinics in 53 sites across 12 countries (Australia, Austria, Canada, Denmark, France, Germany, Italy, Poland, Russia, the Netherlands, the UK, and the USA). Eligible patients had clinical onset after age 18 years, 36 or more cytosine-adenine-guanine repeats in the huntingtin gene, motor symptoms (Unified Huntington's Disease Rating Scale total motor score [UHDRS-TMS] ≥25 points), and reduced independence (UHDRS independence score ≤90%). Patients were randomly assigned (1:1:1:1:1) with centralised interactive-response technology to receive one of four doses of pridopidine (45, 67·5, 90, or 112·5 mg) or placebo orally twice a day for 52 weeks. Randomisation was stratified within centres by neuroleptic drug use. The primary efficacy endpoint was change in the UHDRS-TMS from baseline to 26 weeks, which was assessed in all randomised patients who received at least one dose of study drug and had at least one post-baseline efficacy assessment (full analysis set). Participants and investigators were masked to treatment assignment. This trial is registered with EudraCT (2013-001888-23) and ClinicalTrials.gov (NCT02006472). FINDINGS Between Feb 13, 2014, and July 5, 2016, 408 patients were enrolled and randomly assigned to receive placebo (n=82) or pridopidine 45 mg (n=81), 67·5 mg (n=82), 90 mg (n=81), or 112·5 mg (n=82) twice daily for 26 weeks. The full analysis set included 397 patients (81 in the placebo group, 75 in the 45 mg group, 79 in the 67·5 mg group, 81 in the 90 mg group, and 81 in the 112·5 mg group). Pridopidine did not significantly change the UHDRS-TMS at 26 weeks compared with placebo at any dose. The most frequent adverse events across all groups were diarrhoea, vomiting, nasopharyngitis, falls, headache, insomnia, and anxiety. The most common treatment-related adverse events were insomnia, diarrhoea, nausea, and dizziness. Serious adverse events occurred in the pridopidine groups only and were most frequently falls (n=5), suicide attempt (n=4), suicidal ideation (n=3), head injury (n=3), and aspiration pneumonia (n=3). No new safety or tolerability concerns emerged in this study. One death in the pridopidine 112·5 mg group due to aspiration pneumonia was considered to be possibly related to the study drug. INTERPRETATION Pridopidine did not improve the UHDRS-TMS at week 26 compared with placebo and, thus, the results of secondary or tertiary analyses in previous trials were not replicated. A potentially strong placebo effect needs to be ruled out in future studies. FUNDING Teva Pharmaceutical Industries.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(18)30391-0

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 111

Metadata

Authors
Reilmann, R., McGarry, A., Grachev, I. D., Savola, J.-M., Borowsky, B., Eyal, E., Gross, N., Langbehn, D., Schubert, R., Wickenberg, A. T., Papapetropoulos, S., Hayden, M., Squitieri, F., Kieburtz, K., Landwehrmeyer, G. B., Agarwal, P., Anderson, K. E., Aziz, N. A., Azulay, J.-P., Bachoud-Levi, A. C., Barker, R., Bebak, A., Beuth, M., Biglan, K., Blin, S., Bohlen, S., Bonelli, R., Caldwell, S., Calvas, F., Carlos, J., Castagliuolo, S., Chong, T., Chua, P., Coleman, A., Corey-Bloom, J., Cousins, R., Craufurd, D., Davison, J., Decorte, E., De Michele, G., Dornhege, L., Feigin, A., Gallehawk, S., Gauteul, P., Gonzales, C., Griffith, J., Gustov, A., Guttman, M., Heim, B., Heller, H., Hjermind, L., Illarioshkin, S., Ivanko, L., Jaynes, J., Jenckes, M., Kaminski, B., Kampstra, A., Konkel, A., Kopishinskaya, S., Krystkowiak, P., Komati, S. K., Kwako, A., Lakoning, S., Latipova, G., Leavitt, B., Loy, C., MacFarlane, C., Madsen, L., Marder, K., Mason, S., Mendis, N., Mendis, T., Nemeth, A., Nevitt, L., Norris, V., O'Neill, C., Olivier, A., Orth, M., Owens, A., Panegyres, P., Perlman, S., Preston, J., Priller, J., Puch, A., Quarrell, O., Ragosta, D., Rialland, A., Rickards, H., Romoli, A. M., Ross, C., Rosser, A., Rudzinska, M., Russo, C. V., Saft, C., Segro, V., Seppi, K., Shannon, B., Shprecher, D., Simonin, C., Skitt, Z., Slawek, J., Soliveri, P., Sorbi, S., Squitieri, F., Suski, V., Stepniak, I., Sungmee, P., Temirbaeva, S., Testa, C., Torvin-Moller, A., Uhl, S., Vangsted-Hansen, C., Verny, C., Wall, P., Walker, F., Wasserman, P., Witkowski, G., Wright, J., Zalyalova, Z., & Zielonka, D.
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2019-02
Volume
18
Issue
2
Pages
165-176
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2904241926
Cited by
111
References
6
FWCI
5.00
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. https://app.cochat.ai/papers/10.1016/s1474-4422(18)30391-0
The paper
Reilmann, R., McGarry, A., Grachev, I. D., Savola, J.-M., Borowsky, B., Eyal, E., Gross, N., Langbehn, D., Schubert, R., Wickenberg, A. T., Papapetropoulos, S., Hayden, M., Squitieri, F., Kieburtz, K., Landwehrmeyer, G. B., Agarwal, P., Anderson, K. E., Aziz, N. A., Azulay, J.-P., . . . Zielonka, D. (2019). Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(18)30391-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.